Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
It was déjà vu all over again, albeit compressed in time: when the race started to replace PegIFN+RBV for the treatment of HCV infection, the learnings from HIV drug development and the lessons with HAART provided an excellent template for quick and efficient development. There was early consensus that a search Continue reading 2014: The Year That Changed The Landscape of HCV Therapy
When Pfizer bought dalbavancin and anidulofungin from Vicuron in 2005, it shelled out USD 1.9 billion for both Phase 3 drugs. One can argue whether each drugs had the same commercial value for Pfizer but it is safe to assume that dalbavancin was valued at approx. USD 1 billion at Continue reading Dalbavancin Sale to Actavis
Besides azoles, candins and the polyene class of antifungals there is not much to select from when it comes to systemic fungal infections. Until the recent arrival of voriconazole and posaconazole, infections caused by molds always required amphotericin B to control. Only for Candida several good treatments exist on the Continue reading Nikkomycins Are Finally Getting Some Respect